| Literature DB >> 30987040 |
Cheng-Neng Mi1,2, Hao Wang3, Hui-Qin Chen4, Cai-Hong Cai5, Shao-Peng Li6, Wen-Li Mei7, Hao-Fu Dai8.
Abstract
A phytochemical investigation of the roots of Swietenia macrophylla led to the isolation of seven polyacetylenes, including five new compounds (1-5) and two known ones (6-7). Their structures were elucidated by extensive spectroscopic analysis and detailed comparison with reported data. All the isolates were tested for their cytotoxicity against the human hepatocellular carcinoma cell line BEL-7402, human myeloid leukemia cell line K562, and human gastric carcinoma cell line SGC-7901. Compounds 1 and 6 showed moderate cytotoxicity against the above three human cancer cell lines with IC50 values ranging from 14.3 to 45.4 μM. Compound 4 displayed cytotoxicity against the K562 and SGC-7901 cancer cell lines with IC50 values of 26.2 ± 0.4 and 21.9 ± 0.3 μM, respectively.Entities:
Keywords: Swietenia macrophylla; cytotoxicity; polyacetylene; roots
Mesh:
Substances:
Year: 2019 PMID: 30987040 PMCID: PMC6480581 DOI: 10.3390/molecules24071291
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–7.
1H (500 MHz) and 13C-NMR (125 MHz) data for compounds 1–3 in CDCl3 (δ in ppm, J in Hz).
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
| δH | δC | δH | δC | δH | δC | |
| 1 | 0.99, t (7.4) | 9.5, CH3 | 1.01, t (7.4) | 9.5, CH3 | 1.01, t (7.4) | 9.5, CH3 |
| 2 | 1.72, m | 30.8, CH2 | 1.75, m | 30.8, CH2 | 1.73, m | 30.8, CH2 |
| 3 | 4.34, t (6.4) | 64.1, CH | 4.41, t (6.5) | 64.3, CH | 4.35, t (6.4) | 64.2, CH |
| 4 | 77.3, C | 83.5, C | 77.0, C | |||
| 5 | 69.7, C | 69.5, C | 69.8, C | |||
| 6 | 65.0, C | 74.4, C | 66.3, C | |||
| 7 | 78.6, C | 76.7, C | 77.8, C | |||
| 8 | 3.09, dd (5.0, 10.2) | 18.3, CH2 | 5.86, d (15.9) | 110.5, CH | 2.51, dd (17.3, 6.1) | 24.8, CH2 |
| 9 | 5.50, overlapped | 135.3, CH | 6.30, dd (5.8, 15.9) | 146.3, CH | 3.70, td (6.3, 4.3) | 71.0, CH |
| 10 | 5.48, overlapped | 124.4, CH | 4.00, td (5.8, 1.4) | 75.2, CH | 3.24, td (6.1, 4.3) | 82.1, CH |
| 11 | 4.39 q (6.7) | 67.8, CH | 3.47, m | 74.4, CH | 1.55, m | 29.9, CH2 |
| 12 | 1.60, m; 1.44, m | 37.4, CH2 | 1.46, m | 33.2, CH2 | 1.28–1.29, m | 25.3, CH2 |
| 13 | 1.27–1.28, m | 25.3, CH2 | 1.27–1.28, m | 25.7, CH2 | 1.28–1.29, m | 29.4, CH2 |
| 14 | 1.27–1.28, m | 29.3, CH2 | 1.27–1.28, m | 29.4, CH2 | 1.28–1.29, m | 29.9, CH2 |
| 15 | 1.27–1.28, m | 31.9, CH2 | 1.27–1.28, m | 31.9, CH2 | 1.28–1.29, m | 31.9, CH2 |
| 16 | 1.27–1.28, m | 22.7, CH2 | 1.27–1.28, m | 22.7, CH2 | 1.28–1.29, m | 22.8, CH2 |
| 17 | 0.87 t (6.8) | 14.2, CH3 | 0.87 t (6.9) | 14.2, CH3 | 0.88 t (6.8) | 14.2, CH3 |
| −OCH3 | 3.42, s | 58.5, CH3 | ||||
Figure 2Key 1H-1H COSY and HMBC correlations of compounds 1–5.
Figure 3Key ROESY interactions of compound 2.
1H (500 MHz) and 13C-NMR (125 MHz) data for compounds 4 and 5 in CDCl3 (δ in ppm, J in Hz).
| Position | 4 | 5 | |||||
|---|---|---|---|---|---|---|---|
| δH | δC | δH | δC | Position | δH | δC | |
| 1 | 2.00, s | 65.6, CH | 2.00, s | 66.0, CH | 6′ | 170.1, C | |
| 2 | 68.2, C | 68.0, C | 7′ | 170.0, C | |||
| 3 | 67.0, C | 67.6, C | 8′ | 170.3, C | |||
| 4 | 74.5, C | 71.6, C | 9′ | 170.6, C | |||
| 5 | 2.58, dd (17.4, 6.8) | 24.6, CH2 | 2.62, d (5.6) | 21.8, CH2 | 6″ | 2.11 b, s | 20.8 a, CH3 |
| 6 | 4.13, br t (6.5) | 69.6, CH | 5.11, q (5.6) | 69.1, CH | 7″ | 2.12 b, s | 21.0 a, CH3 |
| 7 | 3.49, m | 73.1, CH | 5.39, dd (4.7, 6.2) | 70.6, CH | 8″ | 2.10 b, s | 20.9 a, CH3 |
| 8 | 3.82, m | 75.1, CH | 5.18, dd (4.7, 6.2) | 71.2, CH | 9″ | 2.10 b, s | 20.8 a, CH3 |
| 9 | 1.55, m | 33.6, CH2 | 5.07, q (6.4) | 71.5, CH | |||
| 10 | 1.33, m1.55, m | 26.0, CH2 | 1.55, m | 30.6, CH2 | |||
| 11 | 1.30, br s | 29.4, CH2 | 1.28, m | 24.6, CH2 | |||
| 12 | 1.30, br s | 31.9, CH2 | 1.28, m | 31.5, CH2 | |||
| 13 | 1.30, br s | 22.7, CH2 | 1.27, m | 22.5, CH2 | |||
| 14 | 0.89, t (6.7) | 14.2, CH3 | 0.86, t (6.9) | 14.1, CH3 | |||
a,b exchangeable.
Cytotoxicity of compounds 1–7 in the human cancer cell lines.
| Compound | Cell Line, IC50 (μM) | ||
|---|---|---|---|
| BEL-7402 | SGC-7901 | K562 | |
|
| 24.9 ± 0.3 | 45.4 ± 0.6 | 16.8 ± 0.1 |
|
| >50 | 26.2 ± 0.4 | 21.9 ± 0.3 |
|
| 14.3 ± 0.4 | 33.4 ± 0.6 | 16.6 ± 0.4 |
| >50 | >50 | >50 | |
| Paclitaxel a | 4.3 ± 0.1 | 4.3 ± 0.2 | 8.6 ± 0.1 |
a Positive control.